TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16510488
Drug: Non-drug users
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-drug users
Study: 2107060
Drug: Niflumic acid
Normalized name: niflumic acid
DrugBank: Niflumic acid (DB04552)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niflumic acid (4 capsules of 250 mg daily)
Study: 6626105
Drug: Self-controlled exposure
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-controlled exposure (Post-treatment)
Study: 31501084
Drug: early salvage
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: early salvage radiotherapy (eSRT) initiated at PSA <0.5 ng/ml
Study: 31501084
Drug: late salvage
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: late salvage radiotherapy (lSRT) initiated at PSA ≥0.5 ng/ml
Study: 12385435
Drug: B-LAC (bismuth,
Approvals — FDA: no, EMA: no, PMDA: no
Description: B-LAC (bismuth, clarithromycin, amoxicillin, and lansoprazole)
Study: 12385435
Drug: B-LAA (bismuth,
Approvals — FDA: no, EMA: no, PMDA: no
Description: B-LAA (bismuth, azithromycin, amoxicillin, and lansoprazole)
Study: 10442379
Drug: Endocrine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine plus UFT therapy
Study: 7605858
Drug: Budesonide (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (9 mg/day for 10 weeks, tapered to 6 mg/day after 8 weeks)
Study: 7605858
Drug: Prednisolone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (40 mg/day for 10 weeks, tapered to 5 mg/day after 2 weeks)
Study: 7605858
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Budesonide and Prednisolone)
Study: 498413
Drug: Daunorubicin (1.0‐1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daunorubicin (1.0‐1.5 mg/kg) as the free drug (for 45 min or 4 h)
Study: 31227307
Drug: Sunitinib followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib followed by deferred CN 24h after the last dose of sunitinib
Study: 28202686
Drug: Simvastatin pre-treatment
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin pre-treatment
Study: 28202686
Drug: Simvastatin post-treatment
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Simvastatin post-treatment
Study: 28202686
Drug: Simvastatin pre-treatment
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin pre-treatment and post-treatment
Study: 25851020
Drug: Ropivacaine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine infusion via saphenous catheter
Study: 25851020
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline infusion via saphenous catheter
Study: 20842754
Drug: Ginger root
Normalized name: Ginger Root
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger root powder capsules
Study: 17490569
Drug: Soluvit treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluvit treatment
Study: 17490569
Drug: Control (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (500 ml normal saline infusion)
Study: 15472178
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) 0.074 mg/kg, administered subcutaneously three times per week until height velocity decreased to less than 1.5 cm/year
Study: 15472178
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered subcutaneously three times per week until height velocity decreased to less than 1.5 cm/year
Study: 7828383
Drug: Simvastatin treatment
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin treatment for 4 weeks
Study: 527635
Drug: Codeine 20
Normalized name: codeine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine 20 mg
Study: 527635
Drug: Noscapine 30
Normalized name: noscapine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noscapine 30 mg
Study: 30873102
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (control group–CG)
Study: 22086510
Drug: Long-axis free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-axis free hand (L-FH)
Study: 20638463
Drug: N-Acetyl-cysteine (NAC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-Acetyl-cysteine (NAC) 1200 mg/day for 14 days
Study: 9751064
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone (1000 microg/day)
Study: 28479257
Drug: Liposomal bupivacaine
Normalized name: bupivacaine liposome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal bupivacaine (LB) with a bridge of 30 mL of 0.5% bupivacaine
Study: 24535359
Drug: dezocine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: dezocine (0.1 mg/kg)
Study: 24535359
Drug: flurbiprofen axetil
Normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
Approvals — FDA: no, EMA: no, PMDA: no
Description: flurbiprofen axetil (1 mg/kg)
Study: 23063354
Drug: FLOT (infusional
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLOT (infusional 5‐FU, leucovorin, oxaliplatin, and docetaxel 50 mg/m(2))
Study: 20739846
Drug: Adjuvant interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant interferon (IFN) therapy
Study: 18379536
Drug: AA-containing peritoneal
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: AA-containing peritoneal dialysis solution
Study: 16391217
Drug: L-arginine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (3 g 3 times a day for 6 months)
Study: 10806282
Drug: lovastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: lovastatin (20 mg)
Study: 29894467
Drug: Masseter muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Masseter muscle injection with type A botulinum toxin
Study: 29894467
Drug: No masseter
Approvals — FDA: no, EMA: no, PMDA: no
Description: No masseter muscle injection with type A botulinum toxin (Control)
Study: 21624491
Drug: AZD1236 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1236 75 mg, twice daily for 6 weeks
Study: 17487212
Drug: Low-fat (20%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat (20% of energy), high-fiber (18 g per 1000 kcals of energy intake), high-fruit and -vegetable (5-8 servings per day) dietary intervention
Study: 12955427
Drug: 1-month clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-month clopidogrel therapy (75 mg p.o. for 1 month)
Study: 12955427
Drug: 6-month clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month clopidogrel therapy (75 mg p.o. for 6 months)
Study: 3896657
Drug: Piretanide (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piretanide (6 mg) once daily
Study: 3896657
Drug: Furosemide (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (40 mg) once daily
Study: 3896657
Drug: Piretanide (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piretanide (6 mg) twice daily at 08.00 and 20.00 hours
Study: 3896657
Drug: Piretanide (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piretanide (6 mg) twice daily at 08.00 and 12.00 hours or 08.00 and 20.00 hours
Study: 30555463
Drug: Novel vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel vaccine approaches for malaria
Study: 17922666
Drug: TNF antagonists
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TNF antagonists
Study: 11936912
Drug: Azithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (500 mg/day for 3 days; n = 133)
Study: 10325453
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg donepezil
Study: 10325453
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg donepezil
Study: 8545142
Drug: Controlled-release (CR)
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled-release (CR) codeine (mean daily dose: 273 ± 78 mg, range: 200-400 mg)
Study: 8594122
Drug: Controlled-release (CR)
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled-release (CR) codeine
Study: 1426661
Drug: Ribomunyl treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribomunyl treatment (4 days) with amoxicillin
Study: 20560941
Drug: Vaginal and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal and sublingual routes
Study: 12098721
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E 500 IU daily for four years
Study: 30251369
Drug: Pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 40 mg/d (n=1,467)
Study: 23326213
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein lycosome formulation (WPL)
Study: 23326213
Drug: Control groups
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control groups (lycopene, WP singular formulation, placebo)
Study: 19385712
Drug: Duloxetine 20-60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 20-60 mg/day orally, once or twice daily (up to 120 mg/day)
Study: 15310635
Drug: Low-dose IT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose IT lidocaine (15 mg) and sufentanil (10 microg)
Study: 15310635
Drug: IT lidocaine
Normalized name: IT-139
DrugBank: IT-139 (DB17145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IT lidocaine (50 mg)
Study: 25268878
Drug: Curcuminoids (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcuminoids (500 mg TID per oral)
Study: 23778938
Drug: Intanza/IDflu (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intanza/IDflu (9 µg for 18-59 y, 15 µg for ≥ 60 y)
Study: 23778938
Drug: Trivalent intramuscular
Normalized name: Afluria, trivalent intramuscular suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent intramuscular vaccine (Vaxigrip(®) 15 µg)
Study: 19336629
Drug: Rapid maxillary
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid maxillary expansion (RME) in addition to fixed appliance therapy
Study: 9247755
Drug: ACE inhibitor-based
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor-based treatment
Study: 8100928
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg rhDNase twice daily for 10 days
Study: 3493794
Drug: Methohexitone 2
Normalized name: Methohexitone
DrugBank: Methohexital (DB00474)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methohexitone 2 mg kg‐1
Study: 24597465
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg TG hydrochloride
Study: 24597465
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg TG hydrochloride
Study: 24597465
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg TG hydrochloride
Study: 24597465
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg TG hydrochloride (multiple doses every 12h for 5 days)
Study: 18956276
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (initially 25 microg, followed by 50 microg and 100 microg every 4 hours)
Study: 18956276
Drug: Vaginal dinoprostone
Normalized name: dinoprostone Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal dinoprostone (3 mg every 6 hours)
Study: 15654934
Drug: Olanzapine treatment
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine treatment for 27.9±20.1 weeks
Study: 10651074
Drug: Interferon-alpha2a (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alpha2a (3 million units subcutaneously, twice a week for 3 months)
Study: 1845847
Drug: Cisplatin 100
Normalized name: CISPLATIN 100MG/VIL (PF) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m2 IV day 1 and etoposide 120 mg/m2 IV days 1, 2, and 3
Study: 1845847
Drug: Cisplatin 100
Normalized name: CISPLATIN 100MG/VIL (PF) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m2 IV day 1 and etoposide 120 mg/m2 IV day 1 and 240 mg/m2 orally days 2 and 3
Study: 6353336
Drug: Cefazoline (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazoline (500 mg intramuscular every 8 hours for 6 doses)
Study: 6353336
Drug: Cotrimoxazole (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotrimoxazole (800 mg sulfametoxazole and 160 mg trimetoprime intramuscular every 12 hours for 6 doses)
Study: 30777064
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy (MT) and stabilizing exercises (SEs)
Study: 11912561
Drug: Psyllium (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium (15 g PSY/d)
Study: 8880382
Drug: Intramuscular and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular and intralesional beta-interferon treatment
Study: 8880382
Drug: Intramuscular beta-interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular beta-interferon treatment
Study: 8880382
Drug: Intralesional beta-interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional beta-interferon treatment
Study: 2114628
Drug: Almitrin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrin (75 mg acute administration)
Study: 2114628
Drug: Almitrin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrin (3 x 25 mg for 6 months)
Study: 2114628
Drug: Almitrin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrin (75 mg additional administration)
Study: 31097067
Drug: Drug-resistant tuberculosis
Normalized name: Mycobacterium tuberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-resistant tuberculosis (DR-TB) patients
Study: 28103819
Drug: Telbivudine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telbivudine (600 mg/day)
Study: 28103819
Drug: Entecavir (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entecavir (0.5 mg/day)
Study: 26016867
Drug: Krill and
Normalized name: Schiff Antarctic Krill and Fish Oil Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Krill and salmon oil (KS oil), 5 1-g capsules for 8 weeks
Study: 26016867
Drug: Control (canola
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (canola oil), 5 1-g capsules for 8 weeks
Study: 23287748
Drug: Standard fluoroscopic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard fluoroscopic assistance (OEC 9900; G.E. HealthCare)
Study: 19363873
Drug: Topical retinoids
Normalized name: tocopheryl retinoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical retinoids (e.g., adapalene, tazarotene)
Study: 19363873
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (topical retinoids with benzoyl peroxide and/or antibiotics and/or hormonal therapy)
Study: 19363873
Drug: Topical retinoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical retinoid monotherapy
Study: 19363873
Drug: Fixed-combination products
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-combination products (topical retinoid/antimicrobial therapy)
Study: 11562516
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid supplementation (500 mg twice daily) for 2 weeks
Study: 7821003
Drug: Potassium dichromate
Normalized name: Potassium dichromate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium dichromate (2.5 mg)
Study: 3133250
Drug: hFSH (human
Approvals — FDA: no, EMA: no, PMDA: no
Description: hFSH (human follicle-stimulating hormone)
Study: 30942033
Drug: Thumb-tack acupuncture
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thumb-tack acupuncture with surrounding needling method plus medication (oral valaciclovir hydrochloride, mecobalamin, vitamin B1)
Study: 30942033
Drug: Medication alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication alone (oral valaciclovir hydrochloride, mecobalamin, vitamin B1)
Study: 30942033
Drug: Thumb-tack acupuncture
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thumb-tack acupuncture with surrounding needling method plus medication
Study: 10757255
Drug: Venlafaxine (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (titrated to a maximum of 150 mg/day)
Study: 10757255
Drug: Amitriptyline (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (titrated to a maximum of 150 mg/day)
Study: 1419551
Drug: Ofloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (200 mg od)
Study: 1419551
Drug: Trimethoprim (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim (200 mg bd)
Study: 1419551
Drug: Co-trimoxazole (trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole (trimethoprim 160 mg and sulphamethoxazole 800 mg bd)
Study: 6362695
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine (2 and 3 ml)
Study: 6362695
Drug: 0.5% amethocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% amethocaine (2 and 3 ml)
Study: 20486336
Drug: PureZone, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: PureZone, a combination therapy involving localized air filtration and pillow encasement
Study: 11574360
Drug: 1.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg ketamine
Study: 7939487
Drug: Supportive psychotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive psychotherapy (in combination with benzodiazepines)
Study: 3148941
Drug: 150 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 micrograms selenium per oral administration after two hours of hard training
Study: 30507604
Drug: Organ dose
Normalized name: argan oil
DrugBank: Argan oil (DB14310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Organ dose modulation with ASiR-V algorithm
Study: 28737262
Drug: 7% hypertonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7% hypertonic saline (HS) inhaled for 8 hours overnight using the tPAD system
Study: 28737262
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (nasal cannula without aerosol)
Study: 28737262
Drug: 7% hypertonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7% hypertonic saline (HS) inhaled
Study: 25310142
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CBT and pharmacotherapy
Study: 16837882
Drug: letrozole 2.5
Normalized name: letrozole 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: letrozole 2.5 mg/day
Study: 16837882
Drug: placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet
Study: 10857519
Drug: Resistive inspiratory
Normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistive inspiratory muscle training (RIMT) for 15 to 20 minutes per session, twice per day, 7 days a week for 6 weeks.
Study: 9663827
Drug: Bismuth carbomer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth carbomer foam enemas (270 mg elemental bismuth)
Study: 20132529
Drug: Buspirone (10‐15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (10‐15 mg/day)
Study: 17132920
Drug: Serum alpha-fetoprotein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum alpha-fetoprotein (AFP) > or = 20 ng/mL
Study: 17132920
Drug: Serum alpha-fetoprotein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum alpha-fetoprotein (AFP) > or = 100 ng/mL
Study: 17132920
Drug: Serum alpha-fetoprotein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum alpha-fetoprotein (AFP) > or = 100 ng/mL with AST <= 2 ULN
Study: 17132920
Drug: Serum alpha-fetoprotein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum alpha-fetoprotein (AFP) > or = 100 ng/mL with AST > 2 ULN
Study: 17132920
Drug: Serum alpha-fetoprotein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum alpha-fetoprotein (AFP) > or = 200 ng/mL with AST > 2 ULN
Study: 10791619
Drug: Oxaceprol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaceprol (400 mg t.i.d.)
Study: 9348578
Drug: UFT (tegafur
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT (tegafur and uracil) 400 mg/day for 1 year after surgery
Study: 3548984
Drug: Diflunisal (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflunisal (500 to 750 mg/day, twice daily)
Study: 3548984
Drug: Ibuprofen (1,600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (1,600 to 2,400 mg/day, four times daily)
Study: 29311084
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg relebactam with 500 mg imipenem-cilastatin, given intravenously every 6 h for 5 doses
Study: 22610770
Drug: Fluency-enhancing therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluency-enhancing therapy
Study: 16171667
Drug: Clonidine (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (single intravenous dose; 4 microg/kg for patients ≤65 years, 3 microg/kg for patients >65 years)
Study: 12855343
Drug: Capsaicin 50
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsaicin 50 microg/ml (0.25, 0.5, 0.75, 1.0, 1.5, 2.0, and 3 ml)
Study: 12855343
Drug: Glycerol (2.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerol (2.5, 5, and 10 ml)
Study: 12855343
Drug: Saline (2.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (2.5, 5, and 10 ml)
Study: 9095707
Drug: Atracurium 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 0.05 mg/kg followed by succinylcholine 1.5 mg/kg
Study: 1683981
Drug: Saline (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (80 ml)
Study: 1683981
Drug: No peritoneal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No peritoneal administration